Cited by 259RNA Interference and Gene DeliveryRNA and protein synthesis mechanismsRNA Research and Splicing

Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency

Open access
Kim, Sun Chang, Sekhon, Simranjeet Singh, Shin, Woo-Ri, Ahn, Gna, Cho, Byung-Kwan, Ahn, Ji-Young, Kim, Yang-Hoon·2022·Molecular & Cellular Toxicology

Abstract

Background mRNA vaccines hold great potential as therapeutic techniques against viral infections due to their efficacy, safety, and large-scale production. mRNA vaccines offer flexibility in development as any protein can be produced from mRNA without altering the production or application process.Objective This review highlights the iterative optimization of mRNA vaccine structural elements that impact the type, specificity, and intensity of immune responses leading to higher translational potency and intracellular stability.Results Modifying the mRNA structural elements particularly the 5' cap, 5'-and 3'-untranslated regions (UTRs), the coding region, and polyadenylation tail help reduce the excessive mRNA immunogenicity and consistently improve its intracellular stability and translational efficiency.Conclusion Further studies regarding mRNA-structural elements and their optimization are needed to create new opportunities for engineering mRNA vaccines.

AI snapshot

Written from the paper’s full text.

TL;DR

This narrative review summarizes how iterative optimization of mRNA vaccine structural elements—the 5′ cap, 5′- and 3′-UTRs, the coding region (ORF), and the poly(A) tail—can reduce excessive mRNA immunogenicity while improving intracellular stability and translational efficiency. It frames these modifications as the basis for the rapid development and >90% efficacy of the BNT162b2 and mRNA-1273 COVID-19 vaccines.

Key findings

  • Modifying mRNA structural elements (5′ cap, 5′- and 3′-UTRs, coding region, poly(A) tail) reduces excessive mRNA immunogenicity and consistently improves intracellular stability and translational efficiency.
  • Higher GC content translates 100-fold higher than a low GC sequence, though high GC can cause problems for mRNA secondary structure; codon optimization affects translation efficiency, mRNA abundance, and protein folding.
  • Nucleoside modification lowers immunogenicity while increasing translation: Kormann et al. reported that 2 weeks after injection of mRNA containing 25% thio-uridine and 25% 5-methylcytidine, Epo levels were five times greater than in untreated animals, whereas unmodified mRNA showed no significant alterations and elicited a considerable immunological response.
  • ARCA-capped mRNA showed translation efficiency twice that of mRNA capped by a conventional cap analog in rabbit reticulocyte lysate, and had a longer half-life in cultured cells; poly(A) tails of approximately 100 nt are described as ideal for mRNA therapeutics (mammalian cell mRNAs carry ~250 nt tails).
  • BNT162b2 and mRNA-1273 both use N1-methylpseudouridine (1mΨ) modification and dsRNA fragment removal; both encode spike proteins with K986P and V987P substitutions, and both have efficacy above 90% (~95%).

Methods

  • Design: narrative review of mRNA vaccine structural element design and modification, drawing on cited primary literature rather than presenting new experimental data.
  • Scope: covers the ORF, 5′- and 3′-UTRs, 5′ capping, the poly(A) tail, immunogenicity elimination, advantages of mRNA vaccines, and the COVID-19 mRNA vaccines BNT162b2 and mRNA-1273.
  • Main analysis: qualitative synthesis organized around each structural element, with a summary table (Table 1) mapping each element's modification to its effect (e.g., UTR length/structure → modulate translation efficiency; cap structure → increase protein synthesis and stability; codon optimization → enhance protein expression; poly(A) tail elongation → increase stability and translational efficiency).

Limitations

  • Stated in the paper: the most difficult task needing attention is striking a balance between translation efficiency and immune response to provide appropriate and safe immunogenicity; further studies on mRNA structural elements and their optimization are needed.
  • Stated in the paper: despite the advantages of mRNA vaccines, many risks remain—long-term effects of mRNA vaccines are unknown, and mRNA is unstable and must be stored at high temperature, making packaging and distribution difficult (the paper also notes cold-chain storage/transport as a major technical and financial challenge).
  • Evident from the text: as a narrative review, it presents no primary data, systematic search strategy, or quantitative synthesis; several cited findings are attributed to other studies, and Moderna's structural elements are described as undisclosed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s13273-021-00171-4

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

30 of 80 cited sources checked · 17 supported · 1 flagged · accuracy not yet measured

  • Premisecitation

    A higher GC sequence translates 100-fold higher than a low GC sequence.

    “Although high GC-content may cause problems for mRNA secondary structure, the higher GC sequence translates 100-fold higher than a low GC sequence (Kudla et al. 2006).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Kudla et al. 2006 source

      The Results (page unavailable) attribute higher protein output from GC-rich GFP to higher mRNA levels, not a higher translation rate. The Discussion likewise says codon optimization increased GFP mRNA levels rather than its translation rate. The claimed 100-fold increase in translation is therefore contrary to the paper's finding. (LLM, conf=0.90)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
  • Premisecitation

    α- and β-globin 3′ UTRs contain sequence features that enhance the translation and stability of mRNA.

    “The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites Sahin et al. 2014 source
    • cites Karikó et al. 1999 source
  • Interpretationcitation

    Modified nucleosides can be used to create mRNA vaccines with significantly improved translation efficiency.

    “The modified nucleosides escape the type interferons (IFNs) induced antiviral pathways and are targeted to break and block invading mRNA; therefore they can be used to create mRNA vaccines with significantly improved translation efficiency (Verbeke et al. 2019).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Verbeke et al. 2019 source
  • Premisecitation

    The translation elongation rate is controlled by the accessibility of cognate tRNA species and codon usage modification.

    “The translation elongation rate is controlled by the accessibility of cognate tRNA species and the codon usage modification to prevent the match rare tRNA sequence of species and integrate sequences that match more common tRNA species (Hanson and Coller 2018).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Hanson and Coller 2018 source
  • Premisecitation

    5′-capping promotes pre-mRNA splicing.

    “Screening mRNA against exonuclease activity, promoting pre-mRNA splicing, and functioning as binding site of eIF4F heterodimeric translation initiation complex are all important functions of 5′-capping (Izaurralde et al. 1994; Gallie 1991).”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites Izaurralde et al. 1994 source
    • cites Gallie 1991 source

      The paper’s opening discussion and Discussion section address the cap’s roles in translation and mRNA stability, not pre-mRNA splicing. Searches for splicing and for cap-dependent removal of introns found no passage stating that capping promotes splicing; a splicing study appears only in the References. (LLM, conf=0.75)

      Experimental — accuracy not yet measured
  • May combine two claims. 30
  • Classified as probably not a substantial claim. 28
  • The quote only partly states this claim. 1
  • May combine two claims.

    Premisecitation

    Modified nucleosides escape type interferons (IFNs) induced antiviral pathways and are targeted to break and block invading mRNA.

    “The modified nucleosides escape the type interferons (IFNs) induced antiviral pathways and are targeted to break and block invading mRNA; therefore they can be used to create mRNA vaccines with significantly improved translation efficiency (Verbeke et al. 2019).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Verbeke et al. 2019 source
  • May combine two claims.

    Premisecitation

    The poly(A) tail steadies mRNA and boosts protein translation.

    “The poly(A) tail steadies mRNA and boosts protein translation, and the length of the poly(A) tail is proportional to translation efficiency.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites Park et al. 2016 source
    • cites Jalkanen et al. 2014 source
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    mRNA is created via a cell-free enzymatic transcription reaction that enables rapid and scalable production.

    “mRNA is created via a cell-free enzymatic transcription reaction that enables rapid and scalable production, as illustrated by the current pandemic's rapid pursuit of RNA vaccines (Verbeke et al. 2021).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Verbeke et al. 2021 source

      In “COVID-19 creates momentum for mRNA vaccines” (page unavailable), the paper discusses in vitro-transcribed (IVT) mRNA, and “Conclusions and perspectives” describes exceptionally rapid development and production of COVID-19 mRNA vaccines. It does not explicitly describe a cell-free enzymatic transcription reaction; the scalable production system it identifies is microfluidic mixing to formulate mRNA-loaded nanoparticles, not transcription itself. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
  • Classified as probably not a substantial claim.

    Premisecitation

    The basic structure of mRNA is made up of a protein-encoding ORF, surrounded by 5′ and 3′ UTRs, a 7-methyl guanosine 5′ cap structure, and a 3′ poly(A) tail.

    “The basic structure of mRNA, same as eukaryotic mRNA, is made up of (i) protein encoding ORF, surrounded by (ii) 5′ and 3′ UTRs, and (iii) a 7-methyl guanosine 5′ cap structure and (iv) a 3′poly(A) tail at the end sides (Verbeke et al. 2019; Schlake et al. 2012; Sahin et al. 2014) (Fig. 1).”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites Verbeke et al. 2019 source
    • cites Schlake et al. 2012 source
    • cites Sahin et al. 2014 source
  • May combine two claims.

    Premisecitation

    N1-methyl-pseudouridine (1mΨ) nucleotide substitution increases base pair stability, resulting in complex secondary structure and improved mRNA translation.

    “N1-methyl-pseudouridine (1mΨ) nucleotide substitution has been found to increase base pair stability, resulting in complex secondary structure and improved mRNA translation (Mauger et al. 2019).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Mauger et al. 2019 source

      The Discussion reports that m1Ψ stabilizes base pairing and mRNA secondary structure and generally increases protein output. But the Results section, “Codon Usage and mRNA Structure Synergize to Determine Ribosome Loading and mRNA Half-Life,” finds that protein output correlates poorly with translation rate and strongly with functional mRNA half-life. Thus the structural and protein-output parts are supported, but “improved mRNA translation” overstates the measured mechanism. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
  • May combine two claims.

    Premisecitation

    BNT162b2 includes N1-methylpseudouridine, optimized codon, high GC sequence, removed dsRNA, and N1-methylpseudouridine modifications.

    “The BNT162b2 includes N1-methylpseudouridine, optimized codon; high GC sequence, removed dsRNA, and N1-methylpseudouridine modifications (Polack et al. 2020).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Polack et al. 2020 source

      The Abstract Methods identifies BNT162b2 as a nucleoside-modified RNA vaccine, supporting the general modification claim. Our copy does not specify N1-methylpseudouridine, codon optimization, high GC content, or removal of double-stranded RNA; searches for those terms found no supporting passage. Page numbers were not available in our copy. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
  • May combine two claims.

    Premisecitation

    Moderna used N1-methylpseudouridine, removed dsRNA, and undisclosed structural elements.

    “Moderna on the other hand used N1-methylpseudouridine, removed dsRNA, and undisclosed structural elements (Baden et al. 2021) (Fig. 2A).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Baden et al. 2021 source

      The Background (p. 1) describes mRNA-1273 as an mRNA vaccine encoding a stabilized spike protein, but does not specify its nucleoside modifications or manufacturing steps. Searches for N1-methylpseudouridine, dsRNA removal, and structural elements found no passage in our copy addressing those claims. (LLM, conf=0.73)

      Experimental — accuracy not yet measured
  • May combine two claims.

    Premisecitation

    Extraction of neutralizing antibodies from COVID-19 patient serum verified the S protein's high immunogenicity, and the receptor binding domain (RBD) and N-terminal domains were also equally immunogenic.

    “The extraction of neutralizing antibodies from COVID-19 patient’s serum verified the S protein’s high immunogenicity, whereas the receptor binding domain (RBD) and N-terminal domains were also equally immunogenic (NTD).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Liu et al. 2020 source

      The opening summary (p. 1) reports neutralizing antibodies from five COVID-19 patients and says the potent antibodies were about equally divided between RBD and NTD targets, indicating that both spike regions are immunogenic. But “Isolation and construction of mAbs” (p. 2) describes sorting spike-binding memory B cells from blood and producing monoclonal antibodies from their sequences, not extracting antibodies from patient serum. (LLM, conf=0.90)

      Experimental — accuracy not yet measured
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The bulk of the mRNA vaccines reported till date have an m7GpppNm cap inserted at the 5′-end during IVT.

    “The bulk of the mRNA vaccines reported till date have an m7GpppNm cap inserted at the 5′-end during IVT (Corbett et al. 2020).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Corbett et al. 2020 source

      Not checked in the free run.

  • May combine two claims. The quote only partly states this claim.

    Premisecitation

    Mice administered HPLC-purified and m1ψ modified mRNA with lipid nanoparticle produced protective antibodies, assisting them in overcoming HIV-1 infection.

    “The findings revealed that mice administered mRNA-LNP produced protective antibodies, assisting them in overcoming HIV-1 infection (Pardi et al. 2017).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Pardi et al. 2017 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Some proteins require delayed translation for appropriate folding, which is guaranteed by uncommon codons.

    “For appropriate folding, some proteins require delayed translation, which is guaranteed by uncommon codons (Kimchi-Sarfaty et al. 2007).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Kimchi-Sarfaty et al. 2007 source

      Checked before — its earlier verdict is held back until a new check runs.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The basic concept underlying mRNA vaccines is to encode the antigen in mRNA and transfer the transcript to the host cell's cytoplasm via a non-viral delivery route, permitting antigen expression and stimulation of an antigen-specific immune response.

    “The basic concept underlying mRNA vaccines is to encode the antigen in mRNA and transfer the transcript to the host cell’s cytoplasm via a non-viral delivery route, permitting antigen expression and stimulation of an antigen-specific immune response (Jackson et al. 2020).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Jackson et al. 2020

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationcitation

    Destabilizing mRNA may be useful in some applications to reduce the time required for protein synthesis.

    “Destabilizing mRNA may be useful in some applications to reduce the time required for protein synthesis.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Premisecitation

    mRNA transcripts containing modified nucleosides are created with lower immunostimulatory activity and a better safety profile.

    “mRNA transcripts containing modified nucleosides, also known as nucleoside-modified mRNAs, are created with lower immunostimulatory activity and a better safety profile.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Verbeke et al. 2019 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    5′-UTR regulatory elements and the length of the 3′-UTR aid translation of protein.

    “5′-UTR regulatory elements and the length of the 3′-UTR aid translation of protein.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Premisecitation

    5-methylcytidine (m5C) and pseudouridine (ψ) nucleotide modifications lower immunogenicity while increasing translation efficiency.

    “5-methylcytidine (m5C) and pseudouridine (ψ) nucleotide modifications are commonly preferred in base-pair alterations as they lower immunogenicity while increasing the efficiency of translation (Weng 2020).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Weng 2020 source
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisenone given

    The 5′ cap regulates pre-mRNA splicing and nuclear export.

    “The 5′ cap regulates pre-mRNA splicing and nuclear export, works as a protective structure that shields RNA from exonuclease cleavage, and initiates mRNA translation.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Premisecitation

    Unmodified mRNA showed no significant alterations and merely elicited a considerable immunological response.

    “Unmodified mRNA, on the other hand, showed no significant alterations and merely elicited a considerable immunological response (Kormann et al. 2011).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Kormann et al. 2011 source
  • May combine two claims.

    Interpretationreasoning

    The translation and stability of mRNA can be improved.

    “The translation and stability of mRNA can be improved and critical tasks have been undertaken to identify desirable mRNA elements.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Premisecitation

    ARCA-capped mRNA boosts and extends protein expression in cultured cells.

    “ARCA-capped mRNA has been shown to boost and extend protein expression in cultured cells (Zohra et al. 2007).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Zohra et al. 2007 source
  • May combine two claims.

    Interpretationreasoning

    Translation efficiency, mRNA abundance, and protein folding may all be affected by codon optimization.

    “Translation efficiency, mRNA abundance, and protein folding may all be affected by codon optimization.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Interpretationreasoning

    These mRNA components can be modified or altered to increase the stability, translation efficiency, and immune-stimulatory feature of mRNA.

    “These components can be modified or altered to increase the stability, translation efficiency, and immune-stimulatory feature of mRNA (Table 1).”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Premisecitation

    mRNA does not interact with the genome and only the parts directly required for the encoded protein expression are present in the basic genetic construct.

    “The mRNA also does not interact with the genome and only the parts directly required for the encoded protein expression are present in this basic genetic construct (Pardi et al. 2018).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Pardi et al. 2018 source

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    UTRs comprise regulatory regions related to mRNA stability, ribosome recognition, interaction with translational machinery components, and mRNA secondary structures.

    “They comprise various regulatory regions related to mRNA stability, ribosome recognition, interaction with translational machinery components, and mRNA secondary structures (Tanguay and Gallie 1996).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Tanguay and Gallie 1996 source

      Checked before — its earlier verdict is held back until a new check runs.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The start codon should include a Kozak sequence.

    “The start codon should include Kozak sequence (Kozak 1986), and the stop codon's sequence can be modified (Liu 2005).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Kozak 1986 source
  • Classified as probably not a substantial claim.

    Premisecitation

    The 7-methylguanosine (m7G) moiety is found at the 5′ end of natural mRNA in the eukaryotic cytoplasm, followed by a triphosphate connection to the first nucleotide (m7GpppN).

    “The 7-methylguanosine (m7G) moiety is found at the 5′ end of natural mRNA in the eukaryotic cytoplasm, followed by a triphosphate connection to the first nucleotide (m7GpppN) (Sahin et al. 2014).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Sahin et al. 2014 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S4 (based). May combine two claims.

    Interpretationnone given

    Optimizing mRNA structural features, particularly the 5′ cap, 5′ and 3′UTRs, the coding region, and the poly(A) tail, increases the mRNA's control of immune responses, resulting in higher translational efficiency.

    “Optimizing the mRNA structural features particularly the 5′ cap, 5′ and 3′UTRs, the coding region, and the poly(A) tail increases the mRNA’s control of immune responses resulting in higher translational efficiency.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Premisenone given

    The efficacy of both the mRNA vaccines is more than 90% (~95% to be precise).

    “The efficacy of both the mRNA vaccines is more than 90% (~ 95% to be precise).”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Premisecitation

    The COVID-19 vaccine candidates demonstrate the structurally modified mRNA approach allows for higher tolerated doses and may be more suitable for producing a fast antibody response.

    “The COVID-19 vaccine candidates demonstrate the structurally modified mRNA approach allows for higher tolerated doses and may be more suitable for producing a fast antibody response (Verbeke et al. 2021).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Verbeke et al. 2021 source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    BNT162b2 uses 5′ UTR human β-globin RNA with optimized Kozak sequence, 3′ UTR AES and mtRNR1 3′ UTR motives, and 110 Poly(A) tail with nucleotide-linker (GCAUAUGACU).

    “In addition, 5′ UTR: human -globin RNA with optimized Kozak sequence, 3′ UTR: AES and mtRNR1 3′ UTR Motives, and 110 Poly(A) tail with nucleotide-linker (GCAUAUGACU) are also used (Orlandini von Niessen et al. 2019).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Orlandini von Niessen et al. 2019 source
  • May combine two claims.

    Premisecitation

    The technique can be easily scaled requiring minimum platform changes during mRNA formulation and production.

    “The technique can be easily scaled requiring minimum platform changes during mRNA formulation and production (Pardi et al. 2018).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Pardi et al. 2018 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S4 (based).

    Interpretationnone given

    Modifying or improving mRNA structural features can boost the mRNA's potential to control innate immune responses, resulting in increased translation capacity and bioavailability.

    “Modifying or improving the structural features can boost the mRNA’s potential to control innate immune responses, resulting in increased translation capacity and bioavailability.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Premisenone given

    Long term effects of the mRNA vaccine are unknown.

    “Despite the advantages of mRNA vaccines there are still many risks involved such as long term effects of the mRNA vaccine are unknown.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationnone given

    mRNA vaccines provide flexibility in development because any protein can be made from mRNA without changing the production or application procedure.

    “mRNA vaccines provide flexibility in development as any protein can be made from mRNA without changing the production or application procedure.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Premisenone given

    Spike proteins with K986P, V987P substitutions are common in both vaccines.

    “Spike proteins with K986P, V987P substitutions are common in both vaccines.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

    Interpretationreasoning

    Optimizing the structure of mRNA can dramatically improve the final result.

    “The final result can be dramatically improved by optimizing the structure of mRNA.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisenone given

    Enzymatic polyadenylation has the disadvantage of producing a variety of RNA species with variable poly(A) tail lengths in each RNA preparation.

    “Enzymatic polyadenylation has the disadvantage of having a variety of RNA species with variable poly(A) tail lengths in each RNA preparation.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

    Premisereasoning

    mRNA is a transient molecule that carries a short translation sequence and has no interaction with the host genome.

    “Furthermore, mRNA is a transient molecule carries a short translation sequence it has no interaction with the host genome.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Protein-based vaccinations are usually made from bacteria, whereas mRNA vaccines can be produced by the host translation machinery, resulting in an antigen that closely resembles the structure of the protein released from the viral genome.

    “Protein-based vaccinations are usually made from bacteria, however mRNA vaccines can be produced by the host translation machinery, resulting in an antigen that closely resembles the structure of the protein released from the viral genome (Park et al. 2021).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Park et al. 2021 source

      Checked before — its earlier verdict is held back until a new check runs.

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Premisenone given

    Vaccine development often requires years of research and testing to ensure efficacy and safety.

    “Vaccine development often requires years of research and testing to ensure efficacy and safety.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Premisecitation

    Poly(A) tails of approximately 100 nt are ideal for synthesizing mRNA therapies because tail size affects mRNA decay by modulating 3′ exonucleolytic degradation.

    “Poly(A) tails of approximately 100 nt are ideal for synthesizing mRNA therapies because tail size affects mRNA decay by modulating 3′ exonucleolytic degradation (Schlake et al. 2012).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Schlake et al. 2012 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    HPLC, anion exchange and affinity chromatography are used in the purification process to remove truncated transcripts.

    “HPLC, anion exchange and affinity chromatography, are used in the purification process to remove truncated transcripts (Weissman et al. 2013).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Weissman et al. 2013 source
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    IVT is a low-cost method of mRNA synthesis.

    “IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Sahin et al. 2014 source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Premisenone given

    The COVID-19 pandemic has increased the interest in mRNA vaccinations.

    “The COVID-19 pandemic has increased the interest in mRNA vaccinations.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisenone given

    mRNA vaccines work on the principle of delivering a transcript that encodes a target antigen or immunogen.

    “mRNA vaccines work on the principle of delivering a transcript that encodes a target antigen or immunogen.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Interpretationreasoning

    IVT of RNA from a DNA template produces RNA with a predetermined poly(A) tail length, which is preferable, particularly for clinical purposes.

    “Contrarily, in vitro transcription (IVT) of RNA from a DNA template produces RNA with a predetermined poly(A) tail length, which is preferable, particularly for clinical purposes.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Interpretationreasoning

    mRNA vaccines have greater biosafety than DNA vaccines because their antigens are translated in the cytoplasm and mRNA is less likely to integrate into the genome.

    “Because antigen translation occurs in the cytoplasm rather than the nucleus; therefore mRNA vaccines have a greater biosafety than DNA vaccines as their antigens are translated into the cytoplasm rather than the nucleus, making it more difficult for the mRNA to integrate into the genome.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Premisenone given

    Adding poly(A) tails lowers mRNA immunogenicity by lowering U content and shielding mRNA in the sequence.

    “Adding poly(A) tails lowers mRNA immunogenicity by lowering U content and shielding mRNA in the sequence.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning

    Because of the ease and speed with which mRNA vaccines may be produced, they are often favored over alternative platforms.

    “Because of the ease and speed with which mRNA vaccines may be produced, they are often favored over alternative platforms.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Premisenone given

    The two mRNA vaccines took less than a year to develop and deploy from start to finish.

    “In contrast, the two mRNA vaccines took less than a year to develop and deploy from start to finish.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Interpretationreasoning

    The rapid creation, manufacture, and excellent effectiveness in preventing SARS-CoV-2 infection show that mRNA-based therapies are ready for application in the future.

    “Their rapid creation, manufacture, and excellent effectiveness in preventing SARS-CoV-2 infection, show that mRNA-based therapies are ready for application in the future.”
    Quote in the paperNot a substantial claim
  • Classified as probably not a substantial claim.

    Premisenone given

    After transfection, mRNA vaccine expresses the protein target (antigen) via translation from mRNA.

    “After transfection, mRNA vaccine expresses the protein target (antigen) via translation from mRNA.”
    Quote in the paperSubstantial claim
52 of 52
  • The paper relies on this without support.

    mRNA is susceptible to degradation and stabilizing it may lead to high expression.

    “The mRNA is susceptible to degradation and stabilizing it may lead to high expression.”
  • The paper relies on this without support.

    The intensity and specificity of the immune responses are influenced by changes in mRNA structure, translational efficiency, and protein-folding machinery.

    “The intensity and specificity of the immune responses are expected to be influenced by these changes.”
  • The paper relies on this without support.

    mRNA is unstable and must be stored at high temperature, making packaging and distribution of vaccine difficult.

    “mRNA is also unstable and must be stored at high temperature making packaging and distribution of vaccine difficult.”
3 of 3

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • UTRs can influence mRNA translation efficiency and resistance to degradation by interacting with RNA-binding proteins and microRNAs.

    “It is known that UTRs are associated with processes of mRNA translation, and by interacting with RNA-binding proteins (RBPs) and microRNAs, UTRs can influence mRNA’s translation efficiency and resistance to degradation [3,4,5,6,7].”

    From Untranslated Region Sequences and the Efficacy of mRNA Vaccines against Tuberculosis (2024) · cites this paper as [6]

    The “5ʹ- and 3ʹ-UTRs” section says that UTR interactions with RNA-binding proteins can influence mRNA degradation and translation efficiency. It does not mention microRNAs as part of that mechanism, so that portion of the attributed claim is unsupported by our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Modifying the structural elements of mRNA including the 5′ cap, 5′-and 3′-untranslated regions, the coding region, and polyadenylation tail help improved the intracellular stability of mRNA.

    “For mRNA vaccine, modifying the structural elements of mRNA including the 5′ cap, 5′-and 3′-untranslated regions, the coding region, and polyadenylation tail help improved the intracellular stability of mRNA (55).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Conflicting mRNA vaccine storage temperatures

    Minor

    The paper says mRNA vaccines must be stored at extremely low temperatures, then says they must be stored at high temperature.

1 of 1

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kim, S. C., Sekhon, S. S., Shin, W.-R., Ahn, G., Cho, B.-K., Ahn, J.-Y., & Kim, Y.-H.
Affiliations
  • Korea Advanced Institute of Science and Technology (KR)
  • Chungbuk National University (KR)
Corresponding author
Kim, Yang-Hoon
Venue
Molecular & Cellular Toxicology
Published
2021-09-20
Volume
18
Issue
1
Pages
1-8
ISSN
  • 1738-642X (ISSN-L)
  • 2092-8467
OpenAlex
W3201215980
Cited by
255
References
57
Citations by year
2026: 38 · 2025: 79 · 2024: 68 · 2023: 46 · 2022: 22 · 2021: 1 · 2020: 1
FWCI
3.59
Type
journal article
Language
en
Open access
Locations
  • Molecular & Cellular Toxicology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
national research foundation of korea (2020R1A6A1A06046235, 2019R1A2C1010860)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords
mRNA vaccines, mRNA stability, translation efficiency, 5' cap, 5' untranslated region, 3' untranslated region, polyadenylation, vaccine optimization, viral infection therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-11-05.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-11-05.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review